Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia

He, Hui; Yin, Ji‐Ye; Li, Xi; Zhang, Yu; Xu, Xiaojing; Zhai, Mengen; Chen, Juan; Qian, Chenyue; Zhou, Hong‐Hao; Liu, Zhao‐Qian

doi:10.1007/s00228-014-1795-6

Cited by 23 publications

(13 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34][35][36] Both the ABCB1*2 and 1236C>T have significant effect on oxaliplatin 37) susceptibility and sunitinib toxicities and survival. 38) Megías-Vericat et al reported the influence of each SNP on the effectiveness of cytarabine plus anthracyclines 39) while He et al emphasized on the impact of the haplotype on the effectiveness of the same therapy. 40) The impact of the ABCB1 1236C>T SNP rather than the ABCB1*2 haplotype in this study is consistent with a previously published clinical study of methadone 41) and paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

Endo-Tsukude

Sasaki

Saeki

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese non-small-cell lung cancer patients treated with oral erlotinib at a standard dose of 150 mg aimed to investigate whether genetic polymorphisms affect erlotinib PK and adverse events. Single nucleotide polymorphisms (SNPs) in genes encoding metabolizing enzymes (CYP1A1, CYP1A2, CYP2D6, CYP3A4, CYP3A5, UGT1A1, UGT2B7, GSTM1, and GSTT1) or efflux transporters (ABCB1, and ABCG2) were analyzed as covariates in a population PK model. The ABCB1 1236C>T (rs1128503) polymorphism, not ABCB1*2 haplotype (1236TT-2677TT-3455TT, rs1128503 TT-rs2032582 TT-rs1045642 TT), was a significant covariate for the apparent clearance (CL/F), with the TT genotype showing a 29.4% decrease in CL/F as compared with the CC and the CT genotypes. A marginally higher incidence of adverse events (mainly skin rash) was observed in the TT genotype group; however, patients with high plasma erlotinib exposure did not always experience skin rash. None of the other SNPs affected PK or adverse events. The ABCB1 genotype is a potential predictor for erlotinib adverse events. Erlotinib might be used with careful monitoring of adverse events in patients with ABCB1 polymorphic variants.

show abstract

Section: Discussionmentioning

confidence: 99%

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

Endo-Tsukude

Sasaki

Saeki

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…In 263 intermediate-risk Chinese AML patients treated with anthracycline and cytarabine, He et al54 investigated the influence of polymorphisms G2677T/A, C1236T, and C3435T. This study reported that patients with TTT haplotype had a longer OS compared with those without TTT haplotype, and hence TTT haplotype was possibly related to the OS, EFS, and relapse in Chinese patients with AML.…”

Section: Abcb1 Variants and Aml Treatmentmentioning

confidence: 99%

<em>ABCB1</em> genetic variants in leukemias: current insights into treatment outcomes

Ankathil¹

2017

PGPM

View full text Add to dashboard Cite

Despite improvements in treatment of different types of leukemia, not all patients respond optimally for a particular treatment. Some treatments will work better for some, while being harmful or ineffective for others. This is due to genetic variation in the form of single-nucleotide polymorphisms (SNPs) that affect gene expression or function and cause inherited interindividual differences in the metabolism and disposition of drugs. Drug transporters are one of the determinants governing the pharmacokinetic profile of chemotherapeutic drugs. The ABCB1 transporter gene transports a wide range of drugs, including drugs used in leukemia treatment. Polymorphisms in the ABCB1 gene do affect intrinsic resistance and pharmacokinetics of several drugs used in leukemia treatment protocols and thereby affect the efficacy of treatment and event-free survival. This review focuses on the impact of three commonly occurring SNPs (1236C>T, 2677G>T/A, and 3435C>T) of ABCB1 on treatment response of various types of leukemia. From the literature available, some of the genotypes and haplotypes of these SNPs have been found to be potential determinants of interindividual variability in drug disposition and pharmacologic response in different types of leukemia. However, due to inconsistencies in the results observed across the studies, additional studies, considering novel genomic methodologies, comprehensive definition of clinical phenotypes, adequate sample size, and uniformity in all the confounding factors, are warranted.

show abstract

“…4 Recent studies have found that MDR1 polymorphism is not only an important genetic factor affecting the response of cancer patients to chemotherapy drugs but is also related to patients’ susceptibility to disease and clinical manifestations. 5–7…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

Objective A relationship between polymorphisms rs1128503 and rs1045642 in the multidrug resistance 1 gene ( MDR1) and susceptibility to hepatocellular carcinoma (HCC) has been reported but is inconclusive. This study was performed to explore the significance of MDR1 polymorphisms rs1128503 and rs1045642 in screening and diagnosis of HCC. Methods Studies of association analyses between MDR1 gene polymorphisms rs1128503 and rs1045642 and HCC were selected from three foreign language databases (PubMed, Cochrane, and Embase) and three Chinese databases (Wanfang, China National Knowledge Infrastructure, and China Knowledge Network) and subjected to meta-analysis. Results We found no significant relationship between the rs1128503 polymorphism and susceptibility to HCC in 4 cohorts and no significant relationship between the rs1045642 polymorphism and susceptibility to HCC in 3 cohorts. Conclusions There was no relationship between polymorphisms rs1128503 or rs1045642 of the MDR1 gene and susceptibility to HCC.

show abstract

Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia

Abstract: The findings suggested the TTT haplotype was possibly related to the OS, RFS, and relapse in Chinese patients with AML.

Cited by 23 publications

References 52 publications

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

<em>ABCB1</em> genetic variants in leukemias: current insights into treatment outcomes

A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma

Contact Info

Product

Resources

About